Trial Search Results
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.
Stanford is currently accepting patients for this trial.
Eli Lilly and Company
Collaborator: Incyte Corporation
- Drug: Baricitinib
- Drug: Placebo
Phase 2/Phase 3
- Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the
time of informed consent.
- Have severe or very severe AA, as determined by all of the following:
- Current AA episode of more than 6 months' duration and hair loss encompassing
≥50% of the scalp, as measured by SALT (AA-IGA of 3 or 4) at screening and
- No spontaneous improvement over the past 6 months.
- Current episode of severe or very severe AA of less than 8 years. Note:
participants who have severe or very severe AA for ≥8 years may be enrolled if
episodes of regrowth, spontaneous or under treatment, have been observed on the
affected areas over the past 8 years.
- Male or nonpregnant, nonbreastfeeding female participants.
- Primarily "diffuse" type of AA.
- Are currently experiencing other forms of alopecia or any other concomitant conditions
that would interfere with evaluations of the effect of study medication on AA.
- Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate
response (for example, absence of significant terminal hair growth after at least 12
weeks of treatment).
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study